The drug semaglutide: what it does, what it doesn't, and why it matters

The biggest myth: semaglutide is a quick fix that anyone can take

The most persistent misconception about semaglutide is that it's a shortcut, a jab (or now a tablet) that bypasses the hard work of managing weight. The MHRA is explicit that GLP-1 medicines are not assessed for quick or cosmetic weight loss, and the licensed indications reflect that. Wegovy is approved alongside a reduced-calorie diet and increased physical activity, not instead of them. The drug amplifies changes you're already working to make; it doesn't replace them.

The second part of the myth is that it's freely available. Semaglutide in all its forms is a Prescription-Only Medicine under UK law. A prescriber must assess your history, current medicines, BMI and any existing conditions before treatment can begin. Our overview of semaglutide for weight management sets out what that assessment involves. Buying semaglutide from a seller who offers it without a clinical consultation isn't just legally irregular, the MHRA has documented serious harms from counterfeit pens containing entirely different substances.

Understanding what the drug actually is tends to clear a lot of this up. Semaglutide is a synthetic analogue of human GLP-1, a hormone released after eating that signals fullness to the brain, slows stomach emptying and helps regulate insulin. It was first developed for type 2 diabetes; its effect on body weight emerged from trial data and led to the higher-dose Wegovy formulation. So if you're asking whether semaglutide is a diabetes drug repurposed for weight loss, the honest answer is: it started that way, and its licensed weight-management products are now separate medicines in their own right.

What the different semaglutide drug names actually mean

One reason people find semaglutide confusing is that it circulates under several names. The active ingredient is always semaglutide; the brand depends on the indication and formulation. The different semaglutide brand names are worth understanding before you try to access treatment, because a prescription for one product cannot simply be swapped for another.

For weight management in the UK, the licensed products are Wegovy (the once-weekly subcutaneous injection, made by Novo Nordisk) and, from June 2026, Wegovy tablets, the first oral GLP-1 medicine approved in the UK for weight management, and the first in Europe. For type 2 diabetes, Ozempic is the injectable semaglutide and Rybelsus is the oral version. These diabetes products carry different doses and are not licensed for weight loss. Ozempic is frequently discussed in weight-loss contexts online, but prescribing it off-label for weight management is outside its UK authorisation. Wegovy as a weight-loss drug is a distinct product with its own licence, that distinction matters when you're deciding what to ask a prescriber about.

The oral tablet route is newer and changes the practical picture for people who'd prefer not to inject. The 25 mg daily maintenance tablet went through its own clinical programme (the OASIS 4 trial, 64 weeks) and recorded around 13.6% average weight loss, rising to approximately 17% among participants who adhered fully throughout the trial. Why semaglutide is classified as a GLP-1 drug explains the receptor mechanism in more depth if the science interests you.

Who the drug semaglutide is licensed to treat (and under what conditions

Wegovy's UK licence covers adults with a BMI of 30 or above, or a BMI of 27 to 29.9 where at least one weight-related condition is present) for example hypertension, type 2 diabetes, high cholesterol or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. NICE's appraisal of Wegovy (TA875) sets out the NHS criteria, which require use within a specialist weight management service for a maximum of two years; you can read NICE's full recommendation for semaglutide (TA875) directly. Private prescribing follows the licensed indications, with a prescriber assessing the whole picture rather than BMI alone.

The drug is a Black Triangle medicine, meaning the MHRA collects additional safety data on it. It is not recommended during pregnancy, breastfeeding or for anyone trying to conceive, and it is not licensed for under-18s. People with a history of pancreatitis, medullary thyroid carcinoma or certain gastrointestinal conditions should discuss those histories with a prescriber before starting. The NHS medicines page on semaglutide covers the key contraindications and side-effect profile in detail.

For anyone looking at the cost side of private treatment, the context around Wegovy pricing in the UK is worth reading before you compare providers. The short version is that a legitimate price covers the prescription, clinical assessment and dispensing, any quote that omits those elements is incomplete.

Side effects: what's common, what to watch for

The side-effect profile of semaglutide is led by the gastrointestinal system. Nausea is the most commonly reported effect, followed by vomiting, diarrhoea, constipation and indigestion. These tend to be most noticeable after starting treatment or following a dose increase, and many people find they settle within the first week or two. Taking the injection or tablet as directed (the tablet specifically on an empty stomach with a small amount of plain water, at least 30 minutes before food) helps manage tolerability.

Less common but more serious effects include acute pancreatitis. Symptoms to act on promptly are severe, persistent abdominal pain that may spread to the back, with or without vomiting. Gallbladder problems have also been reported. Any suspected side effect can be reported to the MHRA through the Yellow Card scheme, which accepts reports from patients as well as healthcare professionals. If you're already on treatment and have a question about something you're experiencing, our aftercare team is available seven days a week.

It's worth knowing that the oral tablet and the injection share a mechanism and a broadly similar side-effect profile, though the studies run to different durations and participant groups. A prescriber reviewing your case will factor in which formulation suits you. Recent developments in semaglutide covers what's changed in the licensing picture since 2025, including the higher 7.2 mg injection dose and the new tablet approval.